---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-010916"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:14:07.583120+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones

## Summary
- Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).
- Cash, equivalents and marketable securities $243.7M as of Dec 31, 2024, providing cash runway into 2027.
- FHD-909 Phase 1 trial enrolling for SMARCA4-mutated cancers (NSCLC primary); preclinical combo data at AACR 2025.
- Selective degradation of ARID1B achieved; program update expected in 2025. CBP and EP300 degraders progressing towards IND.
- Research and development expenses $94.5M (down from $109.7M); G&A $28.4M (down from $32.4M).

## SEC filing metadata
- accession: 0001628280-25-010916
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/0001628280-25-010916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025010916/fhtx-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-010916
- JSON: https://secwatch.observer/filing/0001628280-25-010916.json
- Plain text: https://secwatch.observer/filing/0001628280-25-010916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.